Given (i) the very low rate of clearly disease-causing TP53 variants aged in women with breast cancer aged > 46, (ii) the reasonably high chance of a variant of uncertain significance that could be misclassified and (iii) the increasing likelihood of clonal haematopoiesis, we consider that women presenting with breast cancer after 46 years, without personal or familial history, fulfilling the “Chompret Criteria” should not be tested using a breast panel that includes TP53 (Table 3). The gene discussed is TP53; the disease is breast cancer.